miR-29 Family as Epigenetic Regulators of DNMTs in Prostate Cancer and Benign Prostatic Hyperplasia
Abstract
BACKGROUND: The miR-29 family (miR-29a/b/c) is recognized as a tumor suppressor, directly targeting DNA methyltransferases (DNMTs), key regulators of epigenetic gene silencing. Even though miR-29 has been implicated in tumor progression, its regulatory interaction with DNMT3A/3B, particularly in prostate cancer (PCa), has not been elucidated well. This study was conducted to explore the potential of miR-29a/b/c in targeting DNMT3A/3B in PCa and benign prostatic hyperplasia (BPH), addressing a critical gap in understanding their epigenetic role.
METHODS: This study used tissue samples that were taken surgically from 30 subjects that consisted of 15 diagnosed PCa and 15 BPH patients (as the control group), aged between 18-75 years, with urinary system disorders and had a prostate specific antigen (PSA) value between 1.18 and 56.15 ng/dL. The miR-29a/b/c and DNMT3A/3B expressions were measured using quantitative real-time PCR (qRT-PCR). The variations in mean values across groups, the associations between miR-29a/b/c and DNMT3A/3B expression levels parameters, as well as the correlation between miR-29 levels and DNMT3A/3B variables were then statistically analyzed.
RESULTS: The expression levels of miR-29a/b/c were significantly downregulated in the PCa subjects compared to the BPH subjects (p<0.05), and negative correlations were observed between miR-29a/b/c and DNMT3A/3B in the PCa subjects (p<0.001). In addition, a significant inverse correlation was detected only between miR-29a and DNMT3B in BPH subjects (p<0.05).
CONCLUSION: The results of this study indicated that miR-29a/b/c in PCa may act as a negative regulator directly targeting DNMT3A/3B. These findings support the role of miR-29s in developing miRNA-based strategies for treating PCa.
KEYWORDS: prostate cancer, benign prostatic hyperplasia, epigenetic, DNA methyltransferases-3A/3B, miR-29a/b/c
Full Text:
PDFReferences
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019; 144(8): 1941-53, CrossRef.
Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148-51, CrossRef.
Krieger JN, Lee SWH, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008; 31(Suppl 1): 85-90, CrossRef.
World Health Organization International Agency for Research on Cancer (IARC) [Internet] Latest world cancer statistics - GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [cited 2023 Jan 10]. Available from: https://www.iarc.who.int/.
Hacıislamoğlu A, Evren İ, Yavuzsan AH, Yiğitbaşı İ, Ekşi M, Şeker KG, et al. Prostat spesifik antijenin akut uriner retansiyon sonrası uretral kateter yerleştirilen ve benign prostat hiperplazisi olan hastalarda prostat adenokarsinomu saptamadaki rolü. Yeni Üroloji Dergisi. 2020; 15(3): 158-63, CrossRef.
Čugalj Kern B, Trebušak Podkrajšek K, Kovač J, Šket R, Jenko Bizjan B, Tesovnik T, et al. The role of epigenetic modifications in late complications in type 1 diabetes. Genes. 2022; 13(4): 705, CrossRef.
Ramassone A, Pagotto S, Veronese A, Visone R. Epigenetics and MicroRNAs in Cancer. Int J Mol Sci. 2018; 19(2): 459, CrossRef.
Meiliana A, Dewi NM, Wijaya A. Cancer genetics and epigenetics in cancer risk assessment. Mol Cell Biomed Sci. 2021; 5(2): 41-61, CrossRef.
Chin SP, Dickinson JL, Holloway AF. Epigenetic regulation of prostate cancer. Clin Epigenetics. 2011 Aug; 2(2): 151-69, CrossRef.
Jin B, Li Y, Robertson KD. DNA methylation: Superior or subordinate in the epigenetic hierarchy? Genes Cancer. 2011; 2(6): 607-17, CrossRef.
Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016; 1: 15004, CrossRef.
Ekowati AL, Pramono ZAD, Soeselo DA, Budiyanto A, Astuti I, Mubarika S. hsa-miR-376c-3p in the circulating plasma is upregulated in the elderly Javanese male when compared to their younger counterparts. Indones Biomed J. 2019: 11(3): 225-337, CrossRef.
Konaç E ÖHSS. Üroonkolojide MikroRNA (miRNA)'ların yeri ve önemi. Uronkoloji Bülteni. 2010; 9(1): 3-13, article.
Meiliana A Wijaya A. Identification of biomarkers for prostate cancer. Indones Biomed J. 2014; 6(3): 123-36, CrossRef.
Nguyen TTP, Suman KH, Nguyen TB, Nguyen HT, Do DN. The role of miR-29s in human cancers - An Update. Biomedicines. 2022; 10(9): 2121, CrossRef.
Morita S, Horii T, Kimura M, Ochiya T, Tajima S, Hatada I. miR-29 represses the activities of DNA methyltransferases and DNA demethylases. Int J Mol Sci. 2013; 14(7): 14647-58, CrossRef.
Wu F, Yang Q, Mi Y, Wang F, Cai K, Zhang Y, et al. miR-29b-3p inhibitor alleviates hypomethylation-related aberrations through a feedback loop between miR-29b-3p and DNA methylation in cardiomyocytes. Front Cell Dev Biol. 2022; 10: 788799, CrossRef.
Jiang H, Zhang G, Wu JH, Jiang CP. Diverse roles of miR-29 in cancer (review). Oncol Rep. 2014; 31(4): 1509-16, CrossRef.
Nishikawa R, Goto Y, Kojima S, Enokida H, Chiyomaru T, Kinoshita T, et al. Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int J Oncol. 2014 ;45(1): 401-10, CrossRef.
Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, et al. miR-29s: A family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget. 2015; 6(15): 12837-61, CrossRef.
Cui H, Wang L, Gong P, Zhao C, Zhang S, Zhang K, et al. Deregulation between miR-29b/c and DNMT3A is associated with epigenetic silencing of the CDH1 gene, affecting cell migration and invasion in gastric cancer. PLoS One. 2015; 10(4): e0123926, CrossRef.
Weissmann-Brenner A, Kushnir M, Yanai GL, Aharonov R, Gibori H, Purim O, et al. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Int J Oncol. 2012; 40(6): 2097-103, CrossRef.
Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther. 2012; 11(5): 1166-73, CrossRef.
Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, et al. miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). PLoS One. 2013; 8(8): e70192, CrossRef.
Kwon JJ, Factora TD, Dey S, Kota J. A systematic review of miR-29 in cancer. Mol Ther Oncolytics. 2019; 12: 173-94, CrossRef.
Wu H, Zhang W, Wu Z, Liu Y, Shi Y, Gong J, et al. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma. Cell Death Dis. 2019; 10(2): 48, CrossRef.
Oliveira LH, Schiavinato JL, Fráguas MS, Lucena-Araujo AR, Haddad R, Araújo AG, et al. Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia. Cancer Sci. 2015; 106(10): 1264-77, CrossRef.
Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 2007; 104(40): 15805-10, CrossRef.
Singal R, Das P, Manoharan M, Reis I, Schlesselman J. Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep. 2005; 14(2): 569-73, CrossRef.
Shen H, Wang L, Spitz M, Hong W, Mao L, Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002; 62(17): 4992-5, PMID.
Savitri M, Bintoro UY, Sedana MP, Diansyah MN, Romadhon PZ, Amrita PNA, et al. Circulating plasma miRNA-21 as a superior biomarker compared to CA 15-3: Assessment in healthy age matched subjects and different stage of breast cancer patients. Indones Biomed J. 2020; 12(2): 157-64, CrossRef.
Wang T, Hou J, Jian S, Luo Q, Wei J, Li Z, et al. miR-29b negatively regulates MMP2 to impact gastric cancer development by suppress gastric cancer cell migration and tumor growth. J Cancer. 2018; 9(20): 3776, CrossRef.
Teng Y, Zuo X, Hou M, Zhang Y, Li C, Luo W, et al. A double-negative feedback interaction between microRNA-29b and DNMT3A/3B contributes to ovarian cancer progression. Cell Physiol Biochem. 2016; 39(6): 2341-52, CrossRef.
Alizadeh M, Safarzadeh A, Beyranvand F, Ahmadpour F, Hajiasgharzadeh K, Baghbanzadeh A, et al. The potential role of miR‐29 in health and cancer diagnosis, prognosis, and therapy. J Cell Physiol. 2019; 234(11): 19280-97, CrossRef.
Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics. 2011; 6(3): 388-94, CrossRef.
Zou Y, Li J, Chen Z, Li X, Zheng S, Yi D, et al. miR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients. Carcinogenesis. 2015; 36(6): 676-84, CrossRef.
DOI: https://doi.org/10.18585/inabj.v17i2.3456
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
